Table 4.

Phenotypic and IgE analyses after in vivo DDAB treatments.

	B-cells (% lymphocyte population)		IgE+ B-cells (% total B-cells)
Dose group	%	Cells (×106)	%	Cells (×105)	Total IgE (ng/ml)
4 days
0%	19.78 ± 1.45	0.56 ± 0.07	5.74 ± 0.71	0.31 ±0.02	4255 ± 758
0.0625	21.68± 0.58	1.02 ± 0.01	8.30 ±2.00	0.80 ± 0.02	3268 ± 645
0.1250	25.96 ± 0.73**	2.71 ±0.26**	12.51 ±2.14	3.46 ±0.75	3815 ± 295
0.2500	32.72 ± 1.35**	4.26 ±1.38**	19.01 ±4.33**	8.91 ±2.93**	3585 ± 872
14 days
0%	22.56 ± 1.32	0.79 ±0.11	8.85 ± 1.23	0.70 ±0.01	4479 ± 556
0.0625	21.38± 0.70	1.48 ±0.17	18.92 ±3.91	2.96 ± 0.85	4510 ±532
0.1250	27.70 ± 0.65**	3.69 ±0.36**	13.99 ±2.155	5.10 ± 0.77**	7226 ± 2238
0.2500	33.86 ±1.07**	6.69 ±0.48**	29.70±3.16**	20.10 ±2.92**	15 702 ± 4202**

Levels of significance denoted as compared to vehicle (acetone).

^**p < 0.01

Values shown are means (n = 5)±SE.